Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: a population-based study.

Gustaw-Rothenberg KA, Siedlak SL, Bonda DJ, Lerner A, Tabaton M, Perry G, Smith MA.

Exp Gerontol. 2010 Jan;45(1):47-52. doi: 10.1016/j.exger.2009.10.003. Epub 2009 Oct 9.

2.

Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients.

Maftei M, Thurm F, Schnack C, Tumani H, Otto M, Elbert T, Kolassa IT, Przybylski M, Manea M, von Arnim CA.

PLoS One. 2013 Jul 18;8(7):e68996. doi: 10.1371/journal.pone.0068996. Print 2013.

3.

Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis.

Gustaw KA, Garrett MR, Lee HG, Castellani RJ, Zagorski MG, Prakasam A, Siedlak SL, Zhu X, Perry G, Petersen RB, Friedland RP, Smith MA.

J Neurochem. 2008 Aug;106(3):1350-6. doi: 10.1111/j.1471-4159.2008.05477.x. Epub 2008 May 12.

4.

Autoimmune responses to amyloid structures of Abeta(25-35) peptide and human lysozyme in the serum of patients with progressive Alzheimer's disease.

Gruden MA, Davudova TB, Malisauskas M, Zamotin VV, Sewell RD, Voskresenskaya NI, Kostanyan IA, Sherstnev VV, Morozova-Roche LA.

Dement Geriatr Cogn Disord. 2004;18(2):165-71. Epub 2004 Jun 21.

PMID:
15211072
5.

Antigen-bound and free β-amyloid autoantibodies in serum of healthy adults.

Maftei M, Thurm F, Leirer VM, von Arnim CA, Elbert T, Przybylski M, Kolassa IT, Manea M.

PLoS One. 2012;7(9):e44516. doi: 10.1371/journal.pone.0044516. Epub 2012 Sep 4. Erratum in: PLoS One. 2012;7(11):doi/10.1371/annotation/93ade307-e8d8-40f5-ad57-9e323548838b.

6.

A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease.

Xia W, Yang T, Shankar G, Smith IM, Shen Y, Walsh DM, Selkoe DJ.

Arch Neurol. 2009 Feb;66(2):190-9. doi: 10.1001/archneurol.2008.565.

7.

Beta-amyloid auto-antibodies are reduced in Alzheimer's disease.

Qu BX, Gong Y, Moore C, Fu M, German DC, Chang LY, Rosenberg R, Diaz-Arrastia R.

J Neuroimmunol. 2014 Sep 15;274(1-2):168-73. doi: 10.1016/j.jneuroim.2014.06.017. Epub 2014 Jun 27.

8.

Serum anti-amyloid-beta antibodies and Alzheimer's disease in elderly Korean patients.

Song MS, Mook-Jung I, Lee HJ, Min JY, Park MH.

J Int Med Res. 2007 May-Jun;35(3):301-6.

PMID:
17593857
9.

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.

Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.

Methods. 2012 Apr;56(4):484-93. doi: 10.1016/j.ymeth.2012.03.023. Epub 2012 Apr 6. Review.

PMID:
22503777
10.

Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease.

Jongbloed W, Bruggink KA, Kester MI, Visser PJ, Scheltens P, Blankenstein MA, Verbeek MM, Teunissen CE, Veerhuis R.

J Alzheimers Dis. 2015;45(1):35-43. doi: 10.3233/JAD-142136.

PMID:
25547634
11.

Magnetic bead droplet immunoassay of oligomer amyloid β for the diagnosis of Alzheimer's disease using micro-pillars to enhance the stability of the oil-water interface.

Kim JA, Kim M, Kang SM, Lim KT, Kim TS, Kang JY.

Biosens Bioelectron. 2015 May 15;67:724-32. doi: 10.1016/j.bios.2014.10.042. Epub 2014 Oct 22.

PMID:
25459055
12.

Plasma beta-amyloid as potential biomarker of Alzheimer disease: possibility of diagnostic tool for Alzheimer disease.

Takeda S, Sato N, Rakugi H, Morishita R.

Mol Biosyst. 2010 Oct;6(10):1760-6. doi: 10.1039/c003148h. Epub 2010 Jun 21. Review.

PMID:
20567751
13.

PKCε deficits in Alzheimer's disease brains and skin fibroblasts.

Khan TK, Sen A, Hongpaisan J, Lim CS, Nelson TJ, Alkon DL.

J Alzheimers Dis. 2015;43(2):491-509. doi: 10.3233/JAD-141221.

PMID:
25125477
14.
15.

Serum β-amyloid peptide levels spike in the early stage of Alzheimer-like plaque pathology in an APP/PS1 double transgenic mouse model.

He J, Qiao JP, Zhu S, Xue M, Chen W, Wang X, Tempier A, Huang Q, Kong J, Li XM.

Curr Alzheimer Res. 2013 Nov;10(9):979-86.

PMID:
24117120
16.

The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease.

Wang T, Xiao S, Liu Y, Lin Z, Su N, Li X, Li G, Zhang M, Fang Y.

Int J Geriatr Psychiatry. 2014 Jul;29(7):713-9. doi: 10.1002/gps.4053. Epub 2013 Dec 7.

PMID:
24318929
17.

A sensitive aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid.

Savage MJ, Kalinina J, Wolfe A, Tugusheva K, Korn R, Cash-Mason T, Maxwell JW, Hatcher NG, Haugabook SJ, Wu G, Howell BJ, Renger JJ, Shughrue PJ, McCampbell A.

J Neurosci. 2014 Feb 19;34(8):2884-97. doi: 10.1523/JNEUROSCI.1675-13.2014.

18.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
19.

Circulating immune complexes of Abeta and IgM in plasma of patients with Alzheimer's disease.

Marcello A, Wirths O, Schneider-Axmann T, Degerman-Gunnarsson M, Lannfelt L, Bayer TA.

J Neural Transm (Vienna). 2009 Jul;116(7):913-20. doi: 10.1007/s00702-009-0224-y. Epub 2009 May 5.

20.

Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide.

Brettschneider S, Morgenthaler NG, Teipel SJ, Fischer-Schulz C, Bürger K, Dodel R, Du Y, Möller HJ, Bergmann A, Hampel H.

Biol Psychiatry. 2005 Apr 1;57(7):813-6.

PMID:
15820240

Supplemental Content

Support Center